

Vigmed receives CE-mark approval and first orders for their SWITCH product.

Vigmed announced today that they have received the CE-mark approval for commercial sales of their new product Vigmed® SWiTCH and that several distributors already have placed initial orders for the product

“I am very pleased to announce that Vigmed has been granted CE-approval for SWiTCH by the Notified Body Presafe – in time for our prelaunch campaign, says Vigmed Director of Quality Assurance and Regulatory Affairs, Ola Lindau.

“The launch of SWiTCH is a major milestone for Vigmed, as it offers our distributors a premium priced product range to complement their existing Vigmed portfolio, this enabling them to increase their focus and time offered to sales of Vigmed products”, says CEO Finn Ketler. He continues, “The interest in SWiTCH has been significant as it offers the first safety product of its kind, this is reflected in the fact that the first orders have already been received”.

SWiTCH is a needle protected peripheral arterial catheter, allowing users to control potential blood loss both during insertion as well as during subsequent treatment of the patient. It fulfils the requirement in the EU safety directive and adds a unique product to Vigmed’s range of patented safety devices developed in their continuous efforts to eliminate the risks and hazards of needlestick injuries.

"This specially developed product has been eagerly awaited by Vigmed's partners and end-users, given it broadens the safety offering to the Critical Care and Anesthesia markets”, says Vigmed Director of Sales and Marketing, Mike Dooley. “The commercialization effort started four months ago, and having received the CE-mark, the pre-launch campaign is now being rolled out.”

For further
information contact:

CEO
Finn Ketler
+46 42 600 5311 or

Director, Quality
Assurance and
Regulatory Affairs
Ola Lindau
+46 42 600 5315

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company's Certified Advisor.

Additional information about the company can be found on Vigmed's website: www.vigmed.com/investor